Market
Next country to approve Zepbound for sleep apnea after U.S.?
2
Resolution / Starting Odds
Canada • 25%
European Union • 25%
Australia • 25%
Other • 25%
Official announcements from international health authorities
Story
FDA Approves Eli Lilly's Weight-Loss Drug Zepbound as First Treatment for Obstructive Sleep Apnea
Dec 20, 2024, 10:17 PM
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's weight-loss drug Zepbound (tirzepatide) as the first and only prescription medication for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. This approval allows the drug to be used in combination with a reduced-calorie diet and increased physical activity. Clinical studies have shown that patients treated with Zepbound experienced a mean reduction of 63% in the apnea-hypopnea index (AHI), equating to about 30 fewer breathing interruptions per hour, and up to 50% of patients had no symptoms after one year. The approval opens the door for broader insurance coverage of the medication, marking a significant advancement in the management of obstructive sleep apnea, a condition affecting approximately 39 million adults in the United States.
View original story
Similar markets
United Kingdom • 25%
European Union • 25%
Australia • 25%
Other • 25%
Less than 5 • 25%
5 to 10 • 25%
11 to 15 • 25%
More than 15 • 25%
More than 30% • 25%
20% to 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
More than 60 • 25%
Less than 20 • 25%
20 to 40 • 25%
40 to 60 • 25%
Yes • 50%
No • 50%
European Medicines Agency (EMA) • 25%
Other • 25%
Therapeutic Goods Administration (TGA) • 25%
Medicines and Healthcare products Regulatory Agency (MHRA) • 25%
United States • 25%
Other • 25%
Denmark • 25%
Spain • 25%
Less than 60% • 25%
More than 80% • 25%
70% to 80% • 25%
60% to 70% • 25%